菊粉补充对女性偏头痛患者临床症状、炎症及氧化应激标志物影响的随机临床试验研究方案
这是一项随机双盲安慰剂对照临床试验方案,计划纳入80名20至50岁符合ICHD-3诊断标准的女性偏头痛患者,随机分为每日10克菊粉组(n=40)或每日10克麦芽糊精安慰剂组(n=40),持续12周。主要结局为头痛频率变化,次要结局包括血清连蛋白、高敏C反应蛋白、总抗氧化能力、总氧化状态、一氧化氮、心理状态、生活质量及偏头痛发作持续时间和严重程度。
要点
- 菊粉组每日10克,安慰剂组每日10克麦芽糊精,干预12周。
- 主要结局为头痛频率变化,次要结局含连蛋白、高敏C反应蛋白等指标。
- 研究假设通过菊粉调节肠道菌群、氧化应激和炎症可改善偏头痛结局。
核心结论
- 该临床试验旨在评估菊粉补充对女性偏头痛患者炎症状态、氧化应激、肠道通透性、临床症状、心理健康和生活质量的影响。
- 试验结果可能有助于识别作用机制并为通过调控肠道菌群优化偏头痛管理提供循证临床指南证据。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,纳入80名符合纳入标准的女性偏头痛患者(20至50岁,由神经科医生依据ICHD-3诊断)。
- 参与者分为干预组(每日10克菊粉,n=40)和对照组(每日10克麦芽糊精安慰剂,n=40),持续12周。
- 主要结局为患者头痛频率的变化;次要结局包括血清连蛋白、高敏C反应蛋白、总抗氧化能力、总氧化状态、一氧化氮、心理状态、生活质量及偏头痛发作持续时间和严重程度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Migraine is a complex, chronic, and debilitating multifactorial disorder characterized by recurrent episodes of headache and related symptoms. It typically begins in early ages and is more prevalent in women than in men. Recently, the gut-brain axis has emerged as a new candidate that may be linked to neurological diseases. We hypothesize that selective modulation of the intestinal microbiota, oxidative stress, and inflammation through inulin supplementation may improve clinical outcomes in these patients. Therefore, this study aims to examine the effects of high-performance inulin supplementation on clinical symptoms, mental health, quality of life (QOL), intestinal permeability, and inflammatory and oxidative stress factors in women with migraine. METHODS: This is a randomized, double-blind, placebo-controlled clinical trial involving 80 women with migraine who meet the inclusion criteria (aged between 20 and 50 years with a diagnosis of migraine by a neurologist based on the ICDH-3). Participants will be assigned to receive a daily dose of 10 g of inulin for 12 weeks (intervention group, n = 40) or 10 g of maltodextrin as a placebo for the same duration (control group, n = 40). The primary outcome will measure the variations in the frequency of headache experienced by the patients. Secondary outcomes will encompass serum levels of zonulin, high-sensitive C-reactive protein, total antioxidant capacity, total oxidant status, nitric oxide, mental status, QOL, duration, and severity of migraine attacks. DISCUSSION: This clinical trial aims to evaluate the effect of inulin supplementation on inflammatory status, oxidative stress, intestinal permeability, clinical symptoms, mental health, and QOL in women with migraine. The findings of this trial could contribute to the identification of mechanistic action and evidence-based clinical guidelines that address gut microbiota manipulation to maximize health benefits in the management of clinical outcomes in migraine patients. TRIAL REGISTRATION: Iranian Registry of Clinical Trials ( www.irct.ir ) (ID: IRCT20121216011763N58). Registration date: 23 April 2023. TRIAL STATUS: The protocol is version 3.0, September 17, 2023. Recruitment began August 21, 2023, and is anticipated to be completed by March 22, 2024.
引用
- Vajdi M, Khorvash F, Rouhani MH, et al. Effect of inulin supplementation on clinical symptoms, inflammatory and oxidative stress markers in women with migraine: study protocol for a randomized clinical trial. Trials. 2023. PMID: 37951975. doi:10.1186/s13063-023-07765-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。